SUNRISE Trial for Oral Steroid Dependent Asthma

 

Trial Objective

People with severe asthma are often dependent on oral corticosteroids, such as prednisone, to treat their condition. Researchers are currently investigating whether a new biologic treatment called tezepelumab may help to reduce or remove the need for these steroid medications.

In this study, tezepelumab will be compared against a treatment that does not contain any active medication, called a placebo. Either tezepelumab or the placebo will be given as an injection to study participants.
 

Enrollment

Active Clinical Trials Currently Recruiting

Who Can Participate

Adults ages 18-80 with a documented asthma diagnosis for at least 1 year requiring daily oral steroids for at least 6 months in addition to inhaled steroid treatments. Other criteria will be evaluated to see if you may participate in this study.

Age: 18-80    Gender: Any Gender


Estimated Time Commitment

14 visits over approximately 12 months. Most visits will last about 2 hours, but a few could take up to 4 hours.



Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Not Available

Trial Contact

For more information, contact:

Allen Stevens
720-862-6613

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

AstraZeneca

Principal Investigators


Request More Information

By completing this form, you agree to learn more about this study and see if you qualify.


*
*
*
*
 I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: